T. Rowe Price Associates
ABUS icon

T. Rowe Price Associates’s Arbutus Biopharma ABUS Stock Holding History

T. Rowe Price Associates’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$643K Buy
133,828
+17,838
+15% +$78.3K ﹤0.01% 2506
2026
Q1 		$522K Buy
115,990
+26,774
+30% +$117K ﹤0.01% 2436
2025
Q4 		$430K Buy
89,216
+6,208
+7% +$27.9K ﹤0.01% 2462
2025
Q3 		$377K Buy
83,008
+6,485
+8% +$23.8K ﹤0.01% 2491
2025
Q2 		$237K Buy
76,523
+11,002
+17% +$36.5K ﹤0.01% 2632
2025
Q1 		$229K Buy
65,521
+9,069
+16% +$30.2K ﹤0.01% 2576
2024
Q4 		$185K Buy
56,452
+8,648
+18% +$31.8K ﹤0.01% 2711
2024
Q3 		$185K Buy
47,804
+3,278
+7% +$12.6K ﹤0.01% 2676
2024
Q2 		$138K Buy
44,526
+8,138
+22% +$24.4K ﹤0.01% 2687
2024
Q1 		$94K Buy
36,388
+6,649
+22% +$17.2K ﹤0.01% 2795
2023
Q4 		$75K Buy
29,739
+3,004
+11% +$5.88K ﹤0.01% 2756
2023
Q3 		$55K Buy
26,735
+1,106
+4% +$2.32K ﹤0.01% 2768
2023
Q2 		$59K Buy
25,629
+4,134
+19% +$10.8K ﹤0.01% 2783
2023
Q1 		$66K Buy
21,495
+1,446
+7% +$4.08K ﹤0.01% 2750
2022
Q4 		$47K Buy
20,049
+1,974
+11% +$4.72K ﹤0.01% 2819
2022
Q3 		$35K Buy
18,075
+7,992
+79% +$18.8K ﹤0.01% 2872
2022
Q2 		$27K Buy
+10,083
New +$25.8K ﹤0.01% 2915
2018
Q4 		– Sell
-497,328
Closed -$4.7M – 2559
2018
Q3 		$4.7M Buy
+497,328
New +$4.94M ﹤0.01% 1464

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates's ABUS Position: Q2 2026 in Review

T. Rowe Price Associates increased its Arbutus Biopharma (ABUS) stake by 15% in Q2 2026, buying an estimated $78.3K and bringing the position to 133,828 shares worth $643K. The position accounts for ﹤0.01% of the portfolio, ranked #2506.

T. Rowe Price Associates first reported a position in ABUS in Q3 2018 and has held it in 18 quarters since. The position peaked at $4.7M in Q3 2018. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • T. Rowe Price Associates held 133,828 shares of Arbutus Biopharma worth $643K as of Q2 2026.
  • T. Rowe Price Associates bought 17,838 Arbutus Biopharma shares in Q2 2026, an estimated $78.3K.
  • Arbutus Biopharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2506 holding.
  • T. Rowe Price Associates first reported a position in Arbutus Biopharma in Q3 2018 and has held it in 18 quarters since.
  • T. Rowe Price Associates's Arbutus Biopharma position peaked at $4.7M in Q3 2018.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.